Fig. 4: Clinical outcomes of IDH2-mutated AML patients with co-mutated NPM1 or FLT3-ITD at baseline and the association with residual variants. | Bone Marrow Transplantation

Fig. 4: Clinical outcomes of IDH2-mutated AML patients with co-mutated NPM1 or FLT3-ITD at baseline and the association with residual variants.

From: Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia

Fig. 4

Cumulative incidence of relapse on the left and overall survival on the right for patients based on (a) the presence (IDH2 NGS MRDpos) or absence (IDH2 NGS MRDneg) of residual IDH2 variants or (b) the presence of residual NPM1 and/or FLT3-ITD variants (NPM1/FLT3-ITD NGS MRDpos), the presence of only residual IDH2 variants (IDH2 NGS MRDpos), or the absence of residual variants (NGS MRDneg).

Back to article page